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Abstract
Background: The success of an intervention to prevent the complications of an infection is influenced by the natural
history of the infection. Assumptions about the temporal relationship between infection and the development of
sequelae can affect the predicted effect size of an intervention and the sample size calculation. This study
investigates how a mathematical model can be used to inform sample size calculations for a randomised controlled
trial (RCT) using the example of Chlamydia trachomatis infection and pelvic inflammatory disease (PID).
Methods: We used a compartmental model to imitate the structure of a published RCT. We considered three different
processes for the timing of PID development, in relation to the initial C. trachomatis infection: immediate, constant
throughout, or at the end of the infectious period. For each process we assumed that, of all women infected, the same
fraction would develop PID in the absence of an intervention. We examined two sets of assumptions used to calculate
the sample size in a published RCT that investigated the effect of chlamydia screening on PID incidence. We also
investigated the influence of the natural history parameters of chlamydia on the required sample size.
Results: The assumed event rates and effect sizes used for the sample size calculation implicitly determined the
temporal relationship between chlamydia infection and PID in the model. Even small changes in the assumed PID
incidence and relative risk (RR) led to considerable differences in the hypothesised mechanism of PID development.
The RR and the sample size needed per group also depend on the natural history parameters of chlamydia.
Conclusions: Mathematical modelling helps to understand the temporal relationship between an infection and its
sequelae and can show how uncertainties about natural history parameters affect sample size calculations when
planning a RCT.
Keywords: Sample size calculation, Mathematical model, Compartmental model, Randomised controlled trials,
Chlamydia infection, Pelvic inflammatory disease
Background
In the field of infectious diseases, planning the required
sample size for an intervention trial raises special issues.
The success of an intervention to prevent the disease
complications by reducing exposure to infection is influ-
enced by the natural history of the infection. Different
assumptions about the temporal relationship between
the infection and the development of sequelae can affect
the expected effect size of an intervention. To calculate
the required sample size for a trial investigating the re-
duction in complications of an infection, we need to
make assumptions about the effect size of the interven-
tion (e.g. the reduction in relative risk) and the incidence
of the infection sequelae.
Mathematical models are often used to study the dynam-
ics of infectious disease transmission. Researchers have
also suggested that mathematical models could help to im-
prove the design of randomised controlled trials (RCTs) of
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complex interventions to prevent infectious disease trans-
mission [1–4]. In a recent example, a deterministic com-
partmental model was developed to inform the design and
monitoring of the HIV Prevention Trials Network study
PopART (HPTN 071). PopART is a three-arm cluster-
randomized trial to investigate the effectiveness of anti-
retroviral therapy and other interventions to reduce HIV
transmission at the population level [5, 6]. Mathematical
models are particularly useful for investigating processes
and mechanisms that are difficult to observe in practice
[3], e.g. the development of complications of infections
that might be diagnosed sometime after exposure to the
infection [7]. The effect size of an intervention can be de-
rived within the mathematical modelling framework. The
results obtained for the effect size can then be used to de-
termine the required sample size.
Chlamydia trachomatis (chlamydia) infection in the
lower genital tract can ascend to cause pelvic inflamma-
tory disease (PID) in women which, in turn can cause ec-
topic pregnancy and tubal factor infertility. Chlamydia is
the most common bacterial sexually transmitted infection
in many developed countries [8, 9] and is mostly asymp-
tomatic in women, but treatable with antibiotics if diag-
nosed [10]. There is still considerable uncertainty about
how long after initial infection C. trachomatis ascends to
the upper genital tract, resulting in PID, and the fraction
of infected women who will develop PID [11–13].
There is great interest in interventions that could re-
duce the risk of chlamydia-associated PID because this
might prevent future tubal factor infertility. The Preven-
tion Of Pelvic Infection (POPI) RCT investigated the ef-
fect of offering young women in London a screening test
for chlamydia on the incidence of PID one year later [14,
15]. Women were randomly allocated to an intervention
group, which received immediate testing and treatment
for women with positive chlamydia test results. The con-
trol group reflected routine care, but swabs were col-
lected at baseline and stored. Testing and treatment
were then deferred for one year. The incidence of PID in
the trial was lower in the intervention than the control
arm but the confidence intervals included the null effect
and the investigators argued that the trial was under-
powered [14, 15]. We used published data and assump-
tions from the POPI trial to: investigate how different
assumptions about the temporal relationship between
chlamydia infection and the development of PID can in-
fluence the sample size calculation; and to investigate
how a mathematical model can be used to inform sam-
ple size calculations for an RCT.
Methods
Model
We used a Susceptible-Infected-Susceptible (SIS) com-
partmental model (Fig. 1) to imitate the structure of the
POPI RCT. We ran the model separately for interven-
tion and control groups, using different starting condi-
tions because chlamydia status at baseline differed in the
intervention and in the control group (Additional file 1,
section 1) [16]. Women in the intervention group are all
initially susceptible (S) because they have been tested for
chlamydia and received (presumed) successful treatment
if indicated. In the control group, a percentage of women
is infected (I), reflecting the chlamydia prevalence in the
study population. We used a constant force of infection,
assuming that a single screening test in women participat-
ing in the RCT did not change the population prevalence
of chlamydia, i.e. susceptible women can become infected
at a constant rate λ. Infected women can clear the infec-
tion naturally at rate r. We investigated differences in the
temporal relationship between chlamydia infection and
PID, as described previously, by separating the infectious
period into two stages [16]. The first stage represents in-
fected women without PID (I1) who can progress at rate γ
to the second stage where the infected women have devel-
oped the complication PID (I2). This results in the follow-
ing system of ordinary differential equations:
dS tð Þ
dt
¼ −λS tð Þ þ r I1 tð Þ þ I2 tð Þð Þ
dI1 tð Þ
dt
¼ λS tð Þ− r þ γð ÞI1 tð Þ
dI2 tð Þ
dt
¼ γI1 tð Þ−rI2 tð Þ
The force of infection λ is calculated so that the steady
state prevalence in the model is equal to the prevalence
p of the study population. The duration of infection is
assumed to be exponentially distributed with a mean
duration of 1/r, i.e. some women will clear the infection
Fig. 1 Schematic overview of the model framework. The
Susceptible-Infected-Susceptible (SIS) compartmental model
allows investigating three hypothetical temporal relation assumptions
between chlamydia infection and PID. A susceptible woman (S) can
become infected (I) at a constant rate λ and can clear the infection
naturally at rate r. Numbers indicate when during the chlamydia
infection progression to PID could happen: 1) immediate progression,
2) constant progression, and 3) progression at the end. For the
constant progression, an infected woman can progress at rate γ
from being infected without PID (I1) to being infected with PID
(I2). We set γ = 0 and I = I1 + I2 for immediate progression and
progression at the end. PID, pelvic inflammatory disease.
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rapidly whereas others remain infected for longer time
periods [17, 18].
PID incidence and intervention effect for three types of
progression
We examined three hypothetical mechanisms for the
timing of progression from chlamydia infection to PID
[16]: first, PID could develop soon after C. trachomatis
infects the lower genital tract (immediate progression);
second, PID could develop at any time throughout the
course of lower genital tract infection (constant progres-
sion); or third, PID could develop just before natural
clearance from the lower genital tract (progression at
the end). For each type of progression it is assumed that,
of all women infected, a certain fraction f will develop
PID in the absence of an intervention (Fig. 1). If there is
immediate progression the PID incidence equals fλS, we
set γ = 0 and I = I1 + I2. If PID develops at a constant rate
the PID incidence equals γI1; to achieve the same cumu-
lative PID incidence as the other two types of progres-
sion we set γ ¼ f r1−f $$\gamma =\frac{fr}{1-f}$$. Note, the
mean duration of infection is still 1/r (see Additional file
1, section 1). If PID develops at the end of a chlamydia
infection PID incidence equals frI setting γ = 0 and I = I1
+ I2.
In the absence of an intervention, the PID incidence is
the same for all three types of progression, i.e. the cumu-
lative PID incidence rates in the control group at follow-
up time t are the same. The cumulative PID incidence in
the intervention group at follow-up time t, derived for
each type of progression by the model, is used to calcu-
late the corresponding relative risk (RR) of PID (RR =
risk of PID in intervention group/risk of PID in control
group). The RR is independent of the fraction f for the
immediate progression and for the progression at the
end in contrast to the RR for the constant progression
(Additional file 1, section 2).
Sample size calculations used in the POPI trial
The sample size calculation for the POPI trial was based
on a comparison of two proportions. Standard formulae
used to calculate the sample size need assumptions
about the PID incidence in both groups after the follow-
up period, or about PID incidence in the control group
and the RR (Additional file 1, section 3) [19]. The POPI
trial investigators published two sample size calculations
(Table 1). Before the start of the trial, they assumed a
2 % PID incidence after one year in the control group
and RR = 0.48 resulting in a total sample size needed of
4122 (with 80 % power and a 5 % significance-level), if
there was no loss to follow up, based on a published RCT.
In that RCT, 7 % of women in the intervention group had
a positive chlamydia test result at baseline and the
incidence rates of PID one year later were 8 per 10,000
woman months in the intervention and 18 per 10,000
woman months in the control group (RR 0.44, 95 % CI
0.20-0.90) [20]. During the POPI trial, the investigators re-
vised their sample size calculation, owing to slow enrol-
ment. The revised calculation cited a cohort study
suggesting a higher PID incidence (9.5 % to 12.0 % over
four years in three different groups of women) [21]. In the
revised calculation, they assumed a PID incidence of 3 %
and calculated the sample size needed to detect a RR of
0.44; a sample size of 2274 women would be required to
detect this effect size with 80 % power and a 5 % signifi-
cance level [14, 15].
In this study, we first re-examined the data used for
the two sample size calculations in the POPI trial:
– Scenario 1, 2 % PID incidence and RR = 0.48;
– Scenario 2, 3 % PID incidence and RR = 0.44.
We determined the fraction f such that the PID incidence
in the control group after the follow-up period equals the
PID incidence assumption using baseline values for all
other parameters (Table 1). For each type of progression
from chlamydia to PID, we used the model to derive the in-
cidence of PID in intervention and control groups, and the
corresponding RR. We used the standard formula for cal-
culating the sample size and compared the results with
the original calculation, varying the power of the trial from
10–90 %. A sensitivity analysis for scenario 1 was done by
varying duration of infection and prevalence, keeping
baseline values for all other parameters.
Generic sample size calculation using the mathematical
model
In a second step, we investigated how the mathematical
model can inform sample size calculations in general.
We used the model and the three different types of pro-
gression to examine sample size requirements using differ-
ent values for the natural history parameters of chlamydia
infection instead of assuming a specific PID incidence in
the control group.
First, we used baseline values for all parameters (Table 1)
to derive the PID incidence in the control group, the RR
for each type of progression and the sample size needed
per group. We then changed the duration of infection and
fraction developing PID using baseline values for all other
parameters (Table 1). The analysis was repeated for dif-
ferent values of chlamydia prevalence. We also inves-
tigated the change of PID incidence in the control group
and the RRs while varying the follow-up time from three
to 18 months using baseline values for all other parame-
ters (Table 1).
For all analyses, the sample size needed per group was
calculated using the chi-square test for the comparison of
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two proportions [19]. Analytical results were derived in
Mathematica 10 and numerical solutions were obtained in
R (version 3.1.1) [22, 23]. Code files can be obtained from
the authors on request. This study used published data only
so it did not require approval by an ethical committee.
Results
Sample size calculations used in the POPI trial
Different sets of published assumptions about PID inci-
dence rates and the size of intervention effect lead to dif-
ferent conclusions about the temporal relationship between
chlamydia infection and PID (Fig. 2). In scenario 1, the rela-
tionship between the power of a trial and the sample
size required per group is compatible with the hypoth-
esis that PID can develop throughout the course of infec-
tion (Fig. 2a). Assuming a constant progression rate from
chlamydia to PID results in a RR of 0.49, which is close to
the original RR assumption in the POPI trial (RR = 0.48).
If chlamydia progresses to PID only at the end of the
infectious period, the model predicts a RR of 0.39. In
this scenario, 28.6 % of infected women have to develop
PID to achieve the 2 % PID incidence after one year of
follow-up.
In scenario 2, the assumptions used for the second sam-
ple size calculation (RR = 0.44, 3 % PID incidence) are more
compatible with the hypothesis that PID develops at the
end of a chlamydia infection (Fig. 2b). This model results in
a RR of 0.39, as before. In a model that assumes a constant
progression rate from chlamydia to PID, the predicted
RR = 0.56. In this scenario, 42.9 % of chlamydia-infected
women have to develop PID to achieve an incidence rate
of 3 % after one year of follow-up. The RR and the sample
sizes needed per group are always higher for constant pro-
gression to PID than for progression at the end of infec-
tion (Fig. 2). If chlamydia infection progresses to PID only
at the end of infection, infection can resolve naturally
before they are at risk of PID, whereas with constant pro-
gression the risk of developing PID remains throughout
the infectious period.
Under the hypothesis that C. trachomatis results in
PID almost immediately after infection, the sample size
needed per group is >21,000 for the examined range of
power (data not shown) and the predicted PID incidence
in the intervention group is higher than in the control
group (RR = 1.05 in both scenarios). In this situation, test-
ing and treatment are too late to prevent any PID cases.
On the contrary, women who are successfully treated in
the intervention group are at risk to become newly in-
fected and to develop PID again.
In the sensitivity analysis for scenario 1, the fraction of
women who develop PID in order to achieve the 2 % PID
incidence ranged from 15.9 to 80.3 % at different levels of
chlamydia prevalence and duration of infection (Additional
file 1: Figure S2). For constant progression and progres-
sion at the end of infection, changing duration of infection
influences the RR and the sample size needed per group
Table 1 Parameter values describing sample size calculation, the natural history of chlamydia infection and PID development
Parameters Re-examine POPI trial Generic sample size calculation Source
Baseline values Range Baseline values Range
Sample size calculation
inc PID incidence (per year) 1) 2 % & 2) 3 %a calculated† POPI trial [14]
RR Relative risk 1) 0.48 & 2) 0.44a calculateda POPI trial [14]
t Follow-up time (in days) 365 365 90–540‡ POPI trial [14]
α Significance level 5 % 5 % POPI trial [14]
1-β Power 80 % 10–90 %† 80 % POPI trial [14]
Infection parameter
λ Force of infection (per day) calculated§ calculated§
1/r Duration of infection (in days) 365 365 ± 75 365 365 ± 75 Model [17]¶
p Prevalence of infection 7 % 3–10 %‡ 7 % 3–10 %‡ POPI trial [14]
Progression to PID
f Fraction of women with chlamydia who
progress to PID in absence of testing
calculated† 10 % 7–13 % Model [16]¶
1/γ Infection progression (in days) calculated# calculated#
aFor the three types of progression, PID incidence is used for the control group and RR is calculated per type
†The fraction f and the PID incidence inc in the control group satisfy the equation: fprt = inc
‡Range determined by agreement among authors
§In the absence of the trial, to observe chlamydia prevalence p at steady state: λ ¼ pr1−p
¶Results of a mathematical model which used published trial data
#To achieve the same cumulative PID incidence in all three processes in absence of the trial: γ ¼ f r1−f
PID, pelvic inflammatory disease; RR, relative risk
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more than changing prevalence (see Additional file 1:
Table S1 and Figure S3). The sample size calculated with
constant progression is closer to the POPI trial sam-
ple size calculation than with progression at the end
of infection in 78.5 % of the investigated combinations
(see Additional file 1: Figure S4). The hypothesis of
immediate progression was not investigated because the
estimated RR was >1 in the main analysis.
Generic sample size calculation using the mathematical
model
Assuming a chlamydia prevalence of 7 %, a mean infection
duration of one year, and that 10 % of infected women will
develop PID, we expect a PID incidence of 0.007 after one
year of follow-up. Table 2 shows the resulting RR and the
sample size needed per group for each type of progression
from chlamydia infection to PID. For example, if PID oc-
curs at a constant progression rate, PID incidence is 0.007
per year in the control group and 0.0029 per year in the
intervention group. A chi-squared test with a 5 % two-
sided significance level will have 80 % power to detect this
RR of 0.42 with a sample size of 4654 women in each
group. With this sample size we would expect 33 PID
cases in the control group and 14 PID cases in the inter-
vention group after one year of follow-up.
Varying the duration of infection from 290 to 440 days
and the fraction of women who develop PID from seven
to 13 % results in a median PID incidence of 0.007 per
year (range 0.0041–0.0115, Fig. 3). The incidence of PID
decreases with increasing duration of infection because
fewer women in the control group become newly infected
during the follow-up period. PID incidence increases
with an increasing fraction of women who develop PID.
Figure 4 shows the resulting RR and the sample size
needed per group for constant progression and progres-
sion at the end. Although the RR decreases with increas-
ing duration of infection (Fig. 4a and 4b), the sample size
needed per group is almost unaffected by the change in
duration of infection (Fig. 4c and 4d) or by changing chla-
mydia prevalence (not shown).
For constant progression from chlamydia infection to
PID, the median RR is 0.42 (range 0.36–0.49, Fig. 4a) with
a median sample size needed per group of 4,667 (range
3,644–6,657, Fig. 4c). For progression at the end, the me-
dian RR is 0.39 (range 0.34–0.45, Fig. 4b) and the corre-
sponding sample size needed per group has a median of
4,149 (range 3,154–6,125, Fig. 4d). The RR resulting from
A
B
Fig. 2 Estimated sample sizes under the two assumptions in the
Prevention Of Pelvic (POPI) trial. Plotted curves represent the estimated
sample size needed per group while varying power of the study; for
the original POPI trial (green lines) and for two types of progression;
the one where PID develops at a constant rate throughout infection
(dashed-dotted lines), and the one where PID develops at the end
of infection (dashed lines). The third type of progression where
PID develops immediately after infection is not shown. Panels a and b
separate the two different assumptions about the projected follow-up
incidence of PID in the original POPI trial: scenario 1 with 2 % per year
(Panel a), and scenario 2 with 3 % per year (Panel b). The red circle
represents the sample size with 80 % power in the original POPI
trial. PID, pelvic inflammatory disease; POPI trial, Prevention Of
Pelvic Infection trial
Table 2 Example for sample size calculation

















aBaseline values of Table 1 ‘General sample size calculation’ have been used
for all types of progression
PID, pelvic inflammatory disease
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immediate progression is >1 and the sample size needed
per group is >800,000 (see Additional file 1: Figure S5).
The sample size needed per group depends on PID in-
cidence in the control group and the RR. Hence, the ob-
served pattern of sample size needed for different values
of the infectious duration and fraction developing PID is
a combination of the estimated patterns for PID incidence
and RR. We therefore investigated the relation between
sample size needed per group, RR, and PID incidence
while varying the fraction developing PID. For the hy-
potheses of immediate progression to PID and progres-
sion to PID at the end of chlamydia infection, the RR is
independent of the fraction developing PID, i.e. increasing
the fraction developing PID increases PID incidence and
decreases the sample size needed per group if everything
else is kept constant. For constant progression to PID the
relationship between sample size needed per group and
the fraction developing PID is more complicated because
the RR also depends on the fraction developing PID.
In this situation, PID incidence and RR need to be inves-
Fig. 3 PID incidences per year varying duration of infection and
fraction developing PID. The contour plot presents the PID incidences
per year while varying infection duration and fraction of women
developing PID. The contour lines show for which combinations the
PID incidence remains the same. For all other model parameters the
baseline values were used (Table 1, Generic sample size calculation).
PID, pelvic inflammatory disease.
A B
C D
Fig. 4 Relative risk and sample size per group varying duration of infection and fraction developing PID. The contour plots present the estimated
relative risk (RR) and the corresponding sample size needed per group for the constant progression (Panel a and c) and for the progression at
the end (Panel b and d) while varying infection duration and fraction of women developing PID. The contour lines show for which combinations
the RR and the sample size remain the same. For all other model parameters the baseline values were used (Table 1, Generic sample size
calculation). Note that the RR and sample size needed per group cannot be estimated if the fraction of women who develop PID equals
the prevalence and progression to PID is constant because this results in a division by zero in the RR formula (indicated by the grey area
in (a) and (c))
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tigated together to predict the sample size needed per
group while varying the fraction developing PID (see
Addition file 1, section 4).
The last analysis in our study showed that there are
optimal follow-up times which minimise the sample size
needed per group if all infectious parameters and the
fraction developing PID are fixed (Fig. 5). For constant
progression to PID, a follow-up time of 294 days mini-
mises the sample size needed to 4574 per group with a RR
of 0.358 and a PID incidence of 0.0056 per year. For
progression to PID at the end, a follow-up time of 328 days
minimises the sample size needed to 4106 per group with
a RR of 0.359 and a PID incidence of 0.0063 per year. The
immediate progression hypothesis was not further investi-
gated because RR > 1.
Discussion and conclusion
This study showed how a mathematical model can be
used to inform sample size considerations for RCTs. We
used the example of a screening intervention to prevent
chlamydia infection and PID as a complication by re-
examining published sample size calculations from the
POPI trial. Different sets of assumptions about PID inci-
dence and the RR values used for the sample size calcula-
tion in the POPI trial required different hypotheses about
the temporal relationship between chlamydia and PID.
The sample size calculation in the POPI trial using 2 %
PID incidence per year and RR = 0.48 was compatible with
an assumed constant progression rate from chlamydia in-
fection to PID, whereas with 3 % PID incidence and RR =
0.44 progression from chlamydia to PID would have to
occur at the end of the infectious period. In addition,
using the outputs of our model in a generic sample size
calculation we found large differences in the required
sample size between the POPI trial calculation and our
model prediction. For example, with a constant progres-
sion rate, the median total sample size required was 9,334
and ranged from 7,288 to 13,314, depending on the values
of the infection parameters. This is more than double the
amount considered by the POPI trial investigators in their
first calculation. Not to forget, the RR and the correspond-
ing sample size needed per group depend also on the
other natural history parameters of the infection, however,
not all infection parameters have the same impact.
The strength of this study was the exploration of three
different temporal relationships between chlamydia in-
fection and PID within the same modelling frame-
work. The model does, however, make several simplifying
assumptions. First, the three types of progression are
hypothetical because the immunological and pathogen-
etic mechanisms of PID development are still uncertain
[11–13]. It is not biologically plausible that PID develops
either immediately after C. trachomatis infection or just
before natural clearance; they represent the extreme con-
sequences of early and late progression [16]. Nevertheless,
we found that the type of progression was an important
factor in the sample size consideration. Second, the model
does not include treatment failure for the intervention
group, which would reduce the effect size and result in an
increase in sample size. Third, we assumed no change in
chlamydia test behaviour during the trial, which could ei-
ther increase or decrease the effect size. Fourth, we con-
sidered a closed population, i.e. no loss-to follow-up, so
this would have to be factored into a sample size
A
B
Fig. 5 Relative risk and sample size per group varying follow-up time.
Plotted curves represent the relative risk (Panel a) and the corresponding
sample size needed per group (Panel b) while varying the follow-up time
using for all other model parameters the baseline values (Table 1,
Generic sample size calculation): immediate progression (dotted line);
constant progression (dashed-dotted line); and progression at the
end (dashed line). The red circles indicate the follow-up time
which minimises the sample size needed per group for the constant
progression and progression at the end
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calculation. Finally, we focused on a SIS model but
including an immunity stage did not alter the results in
our study about the sample size considerations in the
POPI trial (Additional file 1, section 7).
To our knowledge this is the first study to investigate
how a mathematical model can be used for sample size
calculations in trials of chlamydia infection and PID pre-
vention. Few mathematical modelling studies explicitly
state assumptions about the timing of progression from
chlamydia to PID, despite their importance in under-
standing chlamydia infection and disease [7]. Smith and
colleagues examined the impact of different intervals be-
tween chlamydia infection and PID development on the
cost-effectiveness of chlamydia screening [24]. Tuite and
colleagues incorporated an assumption that PID develops
at the midpoint of C. trachomatis infectious period to esti-
mate the burden of chlamydial infection [25]. Gray and
colleagues assumed a uniform rate of progression from
chlamydia infection to PID in their investigation of the ef-
fects of a chlamydia vaccine [26]. The advantage of our
approach is that we have compared the implications of
different assumptions for RCT design and planning.
The POPI trial data and our modelling study together
allow an interpretation of the postulated temporal relation-
ship between chlamydial infection and PID in the context of
published RCT evidence. The first set of assumptions used
to calculate the required sample size (chlamydia prevalence
7 %, PID incidence 2 %, RR 0.48) was compatible with the
hypothesis that PID can occur at any time during the infec-
tious period of C. trachomatis. This mechanism is supported
by the effects of similar screening and treatment interven-
tions in other RCTs [15, 20, 27]. The observed chlamydia
prevalence and PID incidence in the POPI trial were close
the actual assumptions but the effect size was smaller, so the
trial was underpowered. The second set of assumptions was
quite similar (chlamydia prevalence 7 %, PID incidence 3 %,
RR 0.44) but the mathematical model showed that these
conditions could only be satisfied if C. trachomatis pro-
gresses to PID at the very end of the infectious period.
This hypothesis lacks biological plausibility, given that
chlamydial infectious load in the lower genital tract should
be lower at the end than the beginning of infection [26].
The results of published RCTs also argue against immedi-
ate progression to PID after C. trachomatis infection [15,
20, 27]. Our model allowed us to examine the probabil-
ity of chlamydia infection progressing to PID. In our
model, both sets of sample size assumptions would re-
quire a high fraction of chlamydia infection progressing to
PID (28.6 % with yearly PID incidence of 2 % and 42.9 %
PID incidence 3 %). Estimates of this size have been used
in several cost-effectiveness studies [7]. However, two re-
cent modelling studies analysing the results of the POPI
trial estimated that 10 % (95 % CI 7–13 %) respectively
12 % (95 % CrI 2–24) of women develop PID [16, 28].
Our approach can be applied to other infections and
diseases. The mathematical model introduced in this
study could be adapted to other sexually transmitted in-
fections such as Mycoplasma genitalium, for which there
is great uncertainty about the natural history, but for
which screening interventions have been advocated [29].
The model can also be extended to incorporate different
types of infection (e.g. those for which immunity after
infection is more important) and other assumptions
about the temporal relationship between the infection
and the complication. This study has implications for
the future planning of RCTs. The relationship between
an infection and its disease complications need to be
understood before planning intervention trials. The find-
ings of this study suggest that mathematical modelling
can be a useful tool for exploring uncertainties about the
natural history parameters of an infection, the temporal
relationship between the infection and its sequelae, and
the implications for sample size calculations in RCTs.
Additional file
Additional file 1: Appendix for method and result section.
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